BRAF Mutation is Associated with an Improved Survival in Glioma—a Systematic Review and Meta-analysis
Newly emerged molecular markers in gliomas provide prognostic values beyond the capabilities of histologic classification. BRAF mutation, especially BRAF V600E, is common in a subset of gliomas and may represent a potential prognostic marker. The aim of our study is to investigate the potential use...
Gespeichert in:
| Veröffentlicht in: | Molecular neurobiology 2018-05, Vol.55 (5), p.3718-3724 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3724 |
|---|---|
| container_issue | 5 |
| container_start_page | 3718 |
| container_title | Molecular neurobiology |
| container_volume | 55 |
| creator | Vuong, Huy Gia Altibi, Ahmed M. A. Duong, Uyen N. P. Ngo, Hanh T. T. Pham, Thong Quang Fung, Kar-Ming Hassell, Lewis |
| description | Newly emerged molecular markers in gliomas provide prognostic values beyond the capabilities of histologic classification.
BRAF
mutation, especially
BRAF
V600E, is common in a subset of gliomas and may represent a potential prognostic marker. The aim of our study is to investigate the potential use of
BRAF
mutations on prognosis of glioma patients. Four electronic databases were searched for potential articles, including PubMed, Scopus, ISI Web of Science, and Virtual Health Library (VHL). Data of hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were directly obtained from original papers or indirectly estimated from Kaplan Meier curve (KMC). A random effect model weighted by inverse variance method was used to calculate the pooled HR. From 705 articles, we finally included 11 articles with 1308 glioma patients for the final analysis. The overall estimates showed that
BRAF
V600E was associated with an improved overall survival (OS) in glioma patients (HR = 0.60; 95% CI = 0.44–0.80). Results for progression-free survival (PFS), however, were not statistically significant (HR = 1.39; 95% CI = 0.82–2.34). In subgroup analyses,
BRAF
V600E showed its effect in improving survival in pediatric and young adult gliomas (under 35 years) but did not have prognostic value in old adult. Additionally,
BRAF
V600E was only associated with a favorable prognosis in lower grade glioma. Our meta-analysis provides evidence that
BRAF
mutation has a favorable prognostic impact in gliomas and its prognostic value might be dependent on patient age and tumor grade. This mutation can be used as a prognostic factor in glioma but additional studies are required to clarify its prognostic value taking into account other confounding factors. |
| doi_str_mv | 10.1007/s12035-017-0599-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1901768831</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1901768831</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-b97135322e60af0ed4c5089f3f942f67e15b5e7e438ac1a384cca370705225223</originalsourceid><addsrcrecordid>eNp1kd1qGzEQhUVpaJy0D9CbIuhNbpSMpJW1e-ma_EFCwWmvhSzPpgr7k-7sOuxdHiJPmCeJjJ0ECoUBweicT6M5jH2VcCwB7AlJBdoIkFaAKQoxfmATaUwhpMzVRzaBvNDCTrN8nx0Q3QEoJcF-YvsqNzpTVk3Y7Y_F7IxfD73vY9vwSHxG1Iboe1zxh9j_4b7hl_V9165T42bo1nHtKx4bfl7FtvbPj0-e34zUY50IgS9wHfEhmVb8GnsvfOOrkSJ9Znulrwi_7M5D9vvs9Nf8Qlz9PL-cz65E0Fb1YllYqY1WCqfgS8BVFkz6RanLIlPl1KI0S4MWM537IL3OsxC8tmDBKJVKH7KjLTdN_HdA6l0dKWBV-QbbgZws0ramea5lkn7_R3rXDl2al5wCJa0pMtgA5VYVupaow9Ldd7H23egkuE0KbpuCS1y3ScGNyfNtRx6WNa7eHK9rTwK1FVC6am6xe3_6_9QXiV2SOA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2021759402</pqid></control><display><type>article</type><title>BRAF Mutation is Associated with an Improved Survival in Glioma—a Systematic Review and Meta-analysis</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Vuong, Huy Gia ; Altibi, Ahmed M. A. ; Duong, Uyen N. P. ; Ngo, Hanh T. T. ; Pham, Thong Quang ; Fung, Kar-Ming ; Hassell, Lewis</creator><creatorcontrib>Vuong, Huy Gia ; Altibi, Ahmed M. A. ; Duong, Uyen N. P. ; Ngo, Hanh T. T. ; Pham, Thong Quang ; Fung, Kar-Ming ; Hassell, Lewis</creatorcontrib><description>Newly emerged molecular markers in gliomas provide prognostic values beyond the capabilities of histologic classification.
BRAF
mutation, especially
BRAF
V600E, is common in a subset of gliomas and may represent a potential prognostic marker. The aim of our study is to investigate the potential use of
BRAF
mutations on prognosis of glioma patients. Four electronic databases were searched for potential articles, including PubMed, Scopus, ISI Web of Science, and Virtual Health Library (VHL). Data of hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were directly obtained from original papers or indirectly estimated from Kaplan Meier curve (KMC). A random effect model weighted by inverse variance method was used to calculate the pooled HR. From 705 articles, we finally included 11 articles with 1308 glioma patients for the final analysis. The overall estimates showed that
BRAF
V600E was associated with an improved overall survival (OS) in glioma patients (HR = 0.60; 95% CI = 0.44–0.80). Results for progression-free survival (PFS), however, were not statistically significant (HR = 1.39; 95% CI = 0.82–2.34). In subgroup analyses,
BRAF
V600E showed its effect in improving survival in pediatric and young adult gliomas (under 35 years) but did not have prognostic value in old adult. Additionally,
BRAF
V600E was only associated with a favorable prognosis in lower grade glioma. Our meta-analysis provides evidence that
BRAF
mutation has a favorable prognostic impact in gliomas and its prognostic value might be dependent on patient age and tumor grade. This mutation can be used as a prognostic factor in glioma but additional studies are required to clarify its prognostic value taking into account other confounding factors.</description><identifier>ISSN: 0893-7648</identifier><identifier>EISSN: 1559-1182</identifier><identifier>DOI: 10.1007/s12035-017-0599-y</identifier><identifier>PMID: 28534272</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Brain Neoplasms - genetics ; Brain Neoplasms - mortality ; Cell Biology ; Glioma ; Glioma - genetics ; Glioma - mortality ; Humans ; Medical prognosis ; Meta-analysis ; Mutation ; Neurobiology ; Neurology ; Neurosciences ; Prognosis ; Proto-Oncogene Proteins B-raf - genetics ; Statistical analysis ; Survival ; Survival Rate ; Systematic review</subject><ispartof>Molecular neurobiology, 2018-05, Vol.55 (5), p.3718-3724</ispartof><rights>Springer Science+Business Media New York 2017</rights><rights>Molecular Neurobiology is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-b97135322e60af0ed4c5089f3f942f67e15b5e7e438ac1a384cca370705225223</citedby><cites>FETCH-LOGICAL-c372t-b97135322e60af0ed4c5089f3f942f67e15b5e7e438ac1a384cca370705225223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12035-017-0599-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12035-017-0599-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27907,27908,41471,42540,51302</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28534272$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vuong, Huy Gia</creatorcontrib><creatorcontrib>Altibi, Ahmed M. A.</creatorcontrib><creatorcontrib>Duong, Uyen N. P.</creatorcontrib><creatorcontrib>Ngo, Hanh T. T.</creatorcontrib><creatorcontrib>Pham, Thong Quang</creatorcontrib><creatorcontrib>Fung, Kar-Ming</creatorcontrib><creatorcontrib>Hassell, Lewis</creatorcontrib><title>BRAF Mutation is Associated with an Improved Survival in Glioma—a Systematic Review and Meta-analysis</title><title>Molecular neurobiology</title><addtitle>Mol Neurobiol</addtitle><addtitle>Mol Neurobiol</addtitle><description>Newly emerged molecular markers in gliomas provide prognostic values beyond the capabilities of histologic classification.
BRAF
mutation, especially
BRAF
V600E, is common in a subset of gliomas and may represent a potential prognostic marker. The aim of our study is to investigate the potential use of
BRAF
mutations on prognosis of glioma patients. Four electronic databases were searched for potential articles, including PubMed, Scopus, ISI Web of Science, and Virtual Health Library (VHL). Data of hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were directly obtained from original papers or indirectly estimated from Kaplan Meier curve (KMC). A random effect model weighted by inverse variance method was used to calculate the pooled HR. From 705 articles, we finally included 11 articles with 1308 glioma patients for the final analysis. The overall estimates showed that
BRAF
V600E was associated with an improved overall survival (OS) in glioma patients (HR = 0.60; 95% CI = 0.44–0.80). Results for progression-free survival (PFS), however, were not statistically significant (HR = 1.39; 95% CI = 0.82–2.34). In subgroup analyses,
BRAF
V600E showed its effect in improving survival in pediatric and young adult gliomas (under 35 years) but did not have prognostic value in old adult. Additionally,
BRAF
V600E was only associated with a favorable prognosis in lower grade glioma. Our meta-analysis provides evidence that
BRAF
mutation has a favorable prognostic impact in gliomas and its prognostic value might be dependent on patient age and tumor grade. This mutation can be used as a prognostic factor in glioma but additional studies are required to clarify its prognostic value taking into account other confounding factors.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain Neoplasms - genetics</subject><subject>Brain Neoplasms - mortality</subject><subject>Cell Biology</subject><subject>Glioma</subject><subject>Glioma - genetics</subject><subject>Glioma - mortality</subject><subject>Humans</subject><subject>Medical prognosis</subject><subject>Meta-analysis</subject><subject>Mutation</subject><subject>Neurobiology</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Prognosis</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><subject>Statistical analysis</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Systematic review</subject><issn>0893-7648</issn><issn>1559-1182</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kd1qGzEQhUVpaJy0D9CbIuhNbpSMpJW1e-ma_EFCwWmvhSzPpgr7k-7sOuxdHiJPmCeJjJ0ECoUBweicT6M5jH2VcCwB7AlJBdoIkFaAKQoxfmATaUwhpMzVRzaBvNDCTrN8nx0Q3QEoJcF-YvsqNzpTVk3Y7Y_F7IxfD73vY9vwSHxG1Iboe1zxh9j_4b7hl_V9165T42bo1nHtKx4bfl7FtvbPj0-e34zUY50IgS9wHfEhmVb8GnsvfOOrkSJ9Znulrwi_7M5D9vvs9Nf8Qlz9PL-cz65E0Fb1YllYqY1WCqfgS8BVFkz6RanLIlPl1KI0S4MWM537IL3OsxC8tmDBKJVKH7KjLTdN_HdA6l0dKWBV-QbbgZws0ramea5lkn7_R3rXDl2al5wCJa0pMtgA5VYVupaow9Ldd7H23egkuE0KbpuCS1y3ScGNyfNtRx6WNa7eHK9rTwK1FVC6am6xe3_6_9QXiV2SOA</recordid><startdate>20180501</startdate><enddate>20180501</enddate><creator>Vuong, Huy Gia</creator><creator>Altibi, Ahmed M. A.</creator><creator>Duong, Uyen N. P.</creator><creator>Ngo, Hanh T. T.</creator><creator>Pham, Thong Quang</creator><creator>Fung, Kar-Ming</creator><creator>Hassell, Lewis</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QR</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20180501</creationdate><title>BRAF Mutation is Associated with an Improved Survival in Glioma—a Systematic Review and Meta-analysis</title><author>Vuong, Huy Gia ; Altibi, Ahmed M. A. ; Duong, Uyen N. P. ; Ngo, Hanh T. T. ; Pham, Thong Quang ; Fung, Kar-Ming ; Hassell, Lewis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-b97135322e60af0ed4c5089f3f942f67e15b5e7e438ac1a384cca370705225223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain Neoplasms - genetics</topic><topic>Brain Neoplasms - mortality</topic><topic>Cell Biology</topic><topic>Glioma</topic><topic>Glioma - genetics</topic><topic>Glioma - mortality</topic><topic>Humans</topic><topic>Medical prognosis</topic><topic>Meta-analysis</topic><topic>Mutation</topic><topic>Neurobiology</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Prognosis</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><topic>Statistical analysis</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vuong, Huy Gia</creatorcontrib><creatorcontrib>Altibi, Ahmed M. A.</creatorcontrib><creatorcontrib>Duong, Uyen N. P.</creatorcontrib><creatorcontrib>Ngo, Hanh T. T.</creatorcontrib><creatorcontrib>Pham, Thong Quang</creatorcontrib><creatorcontrib>Fung, Kar-Ming</creatorcontrib><creatorcontrib>Hassell, Lewis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Science Database (ProQuest)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular neurobiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vuong, Huy Gia</au><au>Altibi, Ahmed M. A.</au><au>Duong, Uyen N. P.</au><au>Ngo, Hanh T. T.</au><au>Pham, Thong Quang</au><au>Fung, Kar-Ming</au><au>Hassell, Lewis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BRAF Mutation is Associated with an Improved Survival in Glioma—a Systematic Review and Meta-analysis</atitle><jtitle>Molecular neurobiology</jtitle><stitle>Mol Neurobiol</stitle><addtitle>Mol Neurobiol</addtitle><date>2018-05-01</date><risdate>2018</risdate><volume>55</volume><issue>5</issue><spage>3718</spage><epage>3724</epage><pages>3718-3724</pages><issn>0893-7648</issn><eissn>1559-1182</eissn><abstract>Newly emerged molecular markers in gliomas provide prognostic values beyond the capabilities of histologic classification.
BRAF
mutation, especially
BRAF
V600E, is common in a subset of gliomas and may represent a potential prognostic marker. The aim of our study is to investigate the potential use of
BRAF
mutations on prognosis of glioma patients. Four electronic databases were searched for potential articles, including PubMed, Scopus, ISI Web of Science, and Virtual Health Library (VHL). Data of hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were directly obtained from original papers or indirectly estimated from Kaplan Meier curve (KMC). A random effect model weighted by inverse variance method was used to calculate the pooled HR. From 705 articles, we finally included 11 articles with 1308 glioma patients for the final analysis. The overall estimates showed that
BRAF
V600E was associated with an improved overall survival (OS) in glioma patients (HR = 0.60; 95% CI = 0.44–0.80). Results for progression-free survival (PFS), however, were not statistically significant (HR = 1.39; 95% CI = 0.82–2.34). In subgroup analyses,
BRAF
V600E showed its effect in improving survival in pediatric and young adult gliomas (under 35 years) but did not have prognostic value in old adult. Additionally,
BRAF
V600E was only associated with a favorable prognosis in lower grade glioma. Our meta-analysis provides evidence that
BRAF
mutation has a favorable prognostic impact in gliomas and its prognostic value might be dependent on patient age and tumor grade. This mutation can be used as a prognostic factor in glioma but additional studies are required to clarify its prognostic value taking into account other confounding factors.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>28534272</pmid><doi>10.1007/s12035-017-0599-y</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-7648 |
| ispartof | Molecular neurobiology, 2018-05, Vol.55 (5), p.3718-3724 |
| issn | 0893-7648 1559-1182 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1901768831 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Biomedical and Life Sciences Biomedicine Brain Neoplasms - genetics Brain Neoplasms - mortality Cell Biology Glioma Glioma - genetics Glioma - mortality Humans Medical prognosis Meta-analysis Mutation Neurobiology Neurology Neurosciences Prognosis Proto-Oncogene Proteins B-raf - genetics Statistical analysis Survival Survival Rate Systematic review |
| title | BRAF Mutation is Associated with an Improved Survival in Glioma—a Systematic Review and Meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T09%3A59%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BRAF%20Mutation%20is%20Associated%20with%20an%20Improved%20Survival%20in%20Glioma%E2%80%94a%20Systematic%20Review%20and%20Meta-analysis&rft.jtitle=Molecular%20neurobiology&rft.au=Vuong,%20Huy%20Gia&rft.date=2018-05-01&rft.volume=55&rft.issue=5&rft.spage=3718&rft.epage=3724&rft.pages=3718-3724&rft.issn=0893-7648&rft.eissn=1559-1182&rft_id=info:doi/10.1007/s12035-017-0599-y&rft_dat=%3Cproquest_cross%3E1901768831%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2021759402&rft_id=info:pmid/28534272&rfr_iscdi=true |